Latest Announcements

Ganesh Consumer Products Ltd announced its Q1 FY27 results, with EBITDA margin reaching a record 11.2% and PAT growing 31.4% YoY to ₹125 Mn. The company's total income stood at ₹1,903 Mn, with EBITDA at ₹210 Mn and PAT at ₹125 Mn. The company also announced the launch of its ethnic snacks range and Soya Chunks, and plans to manufacture packaged sweets at its Amta unit.

Pondy Oxides & Chemicals Limited has released its Q1FY27 investor presentation, highlighting a strong start to the financial year with revenue, EBITDA, and PAT growing by 56%, 30%, and 32% respectively on a YoY basis. The company has prioritized value-added products, resulting in a record lead EBITDA per ton of INR 21,595, up 28% YoY. The company remains on track to achieve its Target 2030 vision, driven by expanded lead capacities, copper capacity additions, and a focus on operational excellence and sustainability.

R Systems International Limited has announced its financial results for the quarter and six months ended June 30, 2026, reporting revenue growth of 30% and EBITDA growth of 51%.

R Systems International Ltd reported robust H1 2026 performance with revenue growth of 30% and EBITDA growth of 51%.

Viviana Power Tech Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue growing 246% YoY to ₹71.86 crore, EBITDA increasing 232% YoY to ₹11.56 crore, and PAT growing 232% YoY to ₹6.93 crore. The company also announced the proposed disinvestment of its entire shareholding in two subsidiaries, Viviana Life Spaces Private Limited and Aarsh Transformers Private Limited.

R Systems International Limited has announced its financial results for the quarter and six months ended June 30, 2026, with the company's income at ₹6,030.69 and expenses at ₹5,225.62, resulting in a profit of ₹805.07. The company has also approved the appointment of four new directors and the payment of remuneration to non-executive independent directors.

Cholamandalam Investment and Finance Company Ltd reported strong growth in Q1 FY27 with aggregate disbursements increasing 22% YoY to INR29,612 crores, AUM expanding 23% YoY to INR2,54,392 crores, and NIMs improving by 42 bps YoY. The company maintained a strong liquidity and capital position with liquid assets of INR23,984 crores and a capital adequacy ratio of 19.81%. The management expressed confidence in achieving the credit cost guidance of 1.5% for FY27.

Cholamandalam Investment and Finance Company Limited has informed the Exchange about the transcript of the earnings call for the quarter ended 30 June, 2026, where the company reported strong growth in aggregate disbursements, AUM, and profitability, driven by healthy demand trends across all major businesses.

TPL Plastech Ltd reported unaudited financial results for Q1 FY27, with volume growth of 12.1%, revenue from operations of ₹1,243.9 Mn, EBITDA of ₹113.4 Mn, and PAT of ₹65.4 Mn. The company maintained margin stability despite input cost fluctuations and plans to expand its facility in Bhuj.

TPL Plastech Limited has reported its unaudited financial results for the quarter ended June 30, 2026, with a 12.1% volume growth, 37.6% revenue growth, and 19.6% profit after tax growth.

Sanofi India Limited has announced its Q2 2026 financial results, reporting 8% domestic net sales growth and 6% total net sales growth compared to the second quarter of 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by strong sales of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27%.

Sanofi India Limited has informed the Exchange about Re-constitution of the Committees of the Company. The Board of Directors at its meeting held today, considered and approved the Unaudited Financial Results for the quarter and half year ended 30th June 2026. The company reported domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The Insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter.

Aequs Ltd's Q1 FY27 earnings conference call transcript reveals a strong start to the year, with consolidated revenue growing 55% YoY to INR3,955 million. The company's consumer segment nearly tripled, and its aerospace segment grew 40% YoY. However, reported EBITDA was lower than Q4 due to other income and foreign exchange. Excluding these factors, EBITDA improved sequentially, driven by narrowing consumer loss.

Sanofi India Ltd has announced its Q2 2026 financial results, reporting 8% domestic net sales growth and 6% total net sales growth compared to Q2 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by strong performance of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27% in Q2 2026.

Sanofi India Limited has announced its Q2 2026 financial results, reporting 8% domestic net sales growth and 6% total net sales growth compared to Q2 2025. The company's insulin portfolio delivered double-digit growth of 14%, driven by strong performance of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27%.

Sanofi India Ltd has announced its Q2 2026 financial results, with domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by strong performance of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27% in Q2 2026.

Sanofi India Limited has announced its financial results for the quarter ended June 30, 2026, with domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, and profits before tax and exceptional items increased 19% to INR 112 crores.

Aequs Limited has informed the Exchange about Transcript of Earnings Conference Call held on July 29, 2026, pertaining to the Un-audited Financial Results of the Company for the quarter ended June 30, 2026. The company reported a 55% year-on-year growth in consolidated revenue to INR3,955 million, with aerospace growing 40% year-on-year and consumer segment nearly tripling. The company's operational EBITDA improved from INR42 million in Q4 to INR148 million, driven by narrowing consumer loss.

Birlasoft Ltd reported Q1 FY27 earnings with revenue growth of 0.3% in constant currency quarter-on-quarter, but 2.3% in rupee terms, and 7.4% year-on-year. EBITDA margins normalized to 16.1% without one-off items, and cash collections were strong, leading to increased cash balances. The company also signed $168.7 million of TCV signings, up 20% year-on-year, including several AI-led engagements.

Birlasoft Limited has announced its Q1 FY27 earnings, with revenue growth of 0.3% in constant currency quarter-on-quarter and 2.3% in rupee terms. EBITDA margins have normalized to 16.1%, and cash collections have been strong, resulting in increased cash balances. The company has also seen strong deal signings, including a $168.7 million TCV signing, and has renewed and expanded its strategic engagement with a leading financial services player in the U.S.